MCID: ALL009
MIFTS: 51

Allergic Conjunctivitis

Categories: Eye diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Allergic Conjunctivitis

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 15 17 70
Conjunctivitis, Allergic 44
Conjunctivitis Allergic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:11204
MeSH 44 D003233
NCIt 50 C34506
SNOMED-CT 67 231854006
UMLS 70 C0009766

Summaries for Allergic Conjunctivitis

Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to giant papillary conjunctivitis and blepharitis. An important gene associated with Allergic Conjunctivitis is HRH1 (Histamine Receptor H1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ephedrine and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 73 Allergic conjunctivitis (AC) is inflammation of the conjunctiva (the membrane covering the white part of... more...

Related Diseases for Allergic Conjunctivitis

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 604)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 32.0 RNASE3 IL4 CXCL8 CCL11
2 blepharitis 31.9 TNF IL4 CXCL8
3 pollen allergy 31.5 RNASE3 IL5 IL13 IGHE ICAM1 FOXP3
4 papillary conjunctivitis 31.1 IL4 CXCL8 CCL11
5 vernal keratoconjunctivitis 31.0 RNASE3 IL5 IL4 IL13 IGHE CCL11
6 vernal conjunctivitis 30.7 RNASE3 IL4 IGHE IFNG
7 atopic keratoconjunctivitis 30.6 RNASE3 IL5 IL4 IL2 IGHE IFNG
8 bacterial conjunctivitis 30.6 TNF IL10 CXCL8
9 cytokine deficiency 30.4 IL5 IL13
10 allergic rhinitis 30.4 RNASE3 IL5 IL4 IL13 IL10 IGHE
11 keratitis, hereditary 30.4 TNF TLR4 IL10 CXCL8
12 keratopathy 30.4 TNF IL4 ICAM1 CXCL8
13 exercise-induced bronchoconstriction 30.4 RNASE3 IL13
14 trachoma 30.1 TNF IL4 IL10
15 haemophilus influenzae 30.1 TNF CXCL8
16 iridocyclitis 30.0 TNF TLR4 IL10
17 dacryoadenitis 29.9 IL4 IL13 IL10 FOXP3
18 keratoconjunctivitis 29.8 TNF RNASE3 IL5 IL4 IL2 IL13
19 ige responsiveness, atopic 29.8 RNASE3 IL5 IL4 IL13 IL10 IGHE
20 secondary progressive multiple sclerosis 29.8 IL4 IL10 IFNG
21 autoimmune lymphoproliferative syndrome 29.7 TNF IL2 IL10 FOXP3
22 scleritis 29.7 TNF IL5 IL4 IFNG
23 pertussis 29.6 TNF TLR4 IL10 CXCL8 CCL11
24 eye disease 29.6 TNF IL5 IL4 IL2 IL13 IL10
25 hypereosinophilic syndrome 29.6 RNASE3 IL5 IL4 IL2 IL13 IL10
26 myasthenia gravis 29.5 TNF IL4 IL2 IL10 IFNG
27 chlamydia 29.5 TNF TLR4 IL5 IL4 IL10 IFNG
28 urticaria 29.3 TNF RNASE3 IL5 IL4 IL13 IL10
29 chronic conjunctivitis 29.3 TNF RNASE3 IL5 IL4 IL33 IL13
30 latex allergy 29.3 TNF RNASE3 IL5 IL4 IL13 IGHE
31 uveitis 29.1 TNF IL4 IL2 IL10 IFNG ICAM1
32 herpes zoster 29.0 TNF TLR3 IL2 IL10 IFNG
33 bronchitis 29.0 TNF TLR4 RNASE3 IL5 IL4 IL13
34 rhinitis 28.9 TNF RNASE3 IL5 IL4 IL33 IL13
35 allergic asthma 28.8 TLR4 RNASE3 IL5 IL4 IL13 IL10
36 allergic disease 28.5 TNF TLR4 RNASE3 IL5 IL4 IL33
37 contact dermatitis 28.5 TNF TLR4 IL5 IL4 IL33 IL2
38 conjunctival disease 28.5 TNF RNASE3 IL5 IL4 IL33 IL2
39 proteasome-associated autoinflammatory syndrome 1 28.0 TNF TLR4 RNASE3 IL5 IL4 IL13
40 food allergy 27.9 TNF TLR4 RNASE3 IL5 IL4 IL13
41 type 1 diabetes mellitus 27.9 TNF TLR4 SOCS3 IL4 IL2 IL10
42 dermatitis 27.9 TNF SOCS3 RNASE3 IL5 IL4 IL33
43 conjunctivitis 27.8 TNF TLR4 TLR3 SOCS5 RNASE3 PTGDR2
44 diabetes mellitus 27.2 TNF TLR4 TLR3 SOCS3 IL4 IL2
45 dermatitis, atopic 27.1 TNF TLR4 SOCS3 RNASE3 PTGDR2 IL5
46 asthma 26.6 TNF TLR4 TLR3 RNASE3 PTGDR2 IL5
47 ifap syndrome 2 10.6
48 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.4 IL4 IL2
49 virus associated hemophagocytic syndrome 10.4 IL4 IL2
50 cefaclor allergy 10.4 IL5 IL13

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis

Symptoms & Phenotypes for Allergic Conjunctivitis

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.31 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
3 immune system MP:0005387 10.31 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
4 digestive/alimentary MP:0005381 10.29 FOXP3 ICAM1 IFNG IL10 IL13 IL2
5 growth/size/body region MP:0005378 10.29 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
6 endocrine/exocrine gland MP:0005379 10.24 FOXP3 ICAM1 IFNG IL10 IL13 IL2
7 integument MP:0010771 10.11 FOXP3 ICAM1 IFNG IL10 IL13 IL33
8 liver/biliary system MP:0005370 10.02 FOXP3 HRH1 IFNG IL10 IL2 IL4
9 neoplasm MP:0002006 9.86 ICAM1 IFNG IL10 IL2 IL5 TLR3
10 no phenotypic analysis MP:0003012 9.76 FOXP3 IFNG IL10 IL13 IL2 IL33
11 reproductive system MP:0005389 9.73 FOXP3 IFNG IL10 IL13 IL2 IL33
12 respiratory system MP:0005388 9.44 CCL11 FOXP3 IFNG IL10 IL13 IL2

Drugs & Therapeutics for Allergic Conjunctivitis

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4 299-42-3 9294
2
Pseudoephedrine Approved Phase 4 90-82-4 7028
3
Pheniramine Approved Phase 4 86-21-5 4761
4
Alcaftadine Approved Phase 4 147084-10-4 19371515
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Dipivefrin Approved Phase 4 52365-63-6 3105
7
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
8
Montelukast Approved Phase 4 158966-92-8 5281040
9
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
10
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
11
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
12
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
13
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
14
Maleic acid Experimental Phase 4 110-16-7 444266
15
Tranilast Investigational Phase 4 53902-12-8 93543
16 Adrenergic alpha-Agonists Phase 4
17 Adrenergic Agonists Phase 4
18 Nasal Decongestants Phase 4
19 Adrenergic Agents Phase 4
20 Lubricant Eye Drops Phase 4
21 Plasma Substitutes Phase 4
22 Dextrans Phase 4
23 Blood Substitutes Phase 4
24 Anticoagulants Phase 4
25 Respiratory System Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Bronchodilator Agents Phase 4
28 Neuroprotective Agents Phase 4
29 Anti-Bacterial Agents Phase 4
30 Platelet Aggregation Inhibitors Phase 4
31 calcium channel blockers Phase 4
32 Calcium, Dietary Phase 4
33 Cholinergic Agents Phase 4
34 Cholinergic Antagonists Phase 4
35 Leukotriene Antagonists Phase 4
36 Isospaglumic acid Phase 4
37 Viscosupplements Phase 4
38 Protective Agents Phase 4
39 Adjuvants, Immunologic Phase 4
40 Immunologic Factors Phase 4
41 Beta-1,3-glucan Phase 4
42
Calcium Nutraceutical Phase 4 7440-70-2 271
43
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
44
Cetirizine Approved Phase 3 83881-51-0 2678
45
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
46
Bromfenac Approved Phase 3 91714-94-2 60726
47
Budesonide Approved Phase 3 51333-22-3 63006 5281004
48 Dermatologic Agents Phase 3
49 Cyclooxygenase Inhibitors Phase 3
50 Ketorolac Tromethamine Phase 3

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
4 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
5 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
6 The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
7 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
8 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
9 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
10 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
11 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
12 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
13 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
14 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
15 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
16 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
17 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
18 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
19 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
20 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
21 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
22 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
23 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
24 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
25 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
26 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
27 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
28 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ® (Placebo)
29 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
30 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
31 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
32 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
33 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
34 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
35 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
36 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
37 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
38 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
39 Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
40 PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROLLED,60 DAYS, PARALLEL GROUPS, SUPERIORITY STUDY, TO COMPARE THE EFFECTIVENESS AND TOXICITY OF BEPOTASTINE 1.5% PF vs. OLOPATADINE 0.2% WITH BAK IN TREATMENT OF ALLERGIC CONJUNCTIVITIS Recruiting NCT04776096 Phase 4 Bepotastine Besilate 1.5% PF;Olopatadine Hydrochloride 0.2% BAK
41 DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis Not yet recruiting NCT04708821 Phase 4 Dexamethasone ophthalmic insert 0.4Mg;0.2% loteprednol etabonate ophthalmic suspension;olopatadine hydrochloride ophthalmic solution 0.7%
42 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study Terminated NCT00276445 Phase 4 beta-1,3-glucan
43 Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
44 A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy Withdrawn NCT03862053 Phase 4 Manuka honey
45 A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis Unknown status NCT00812799 Phase 3 Oralgen
46 A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis Unknown status NCT01012752 Phase 3
47 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
48 A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily Completed NCT01698814 Phase 3 AL-4943A Ophthalmic Solution;AL-4943A Ophthalmic Solution Vehicle
49 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Completed NCT02082262 Phase 3 AGN-229666
50 A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Completed NCT00424398 Phase 2, Phase 3 Bepreve;Placebo;Bepotastine Besilate

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Antazoline
Antazoline Hydrochloride
Antazoline Phosphate
Astemizole
azelastine
Azelastine hydrochloride
bepotastine
bepotastine besilate
carbinoxamine
Carbinoxamine maleate
Ketorolac Tromethamine
levocabastine
Levocabastine hydrochloride
Loteprednol
loteprednol etabonate
medrysone
Nedocromil
Nedocromil Sodium
olopatadine
Olopatadine hydrochloride
pemirolast
Pemirolast potassium
Pyrilamine
Pyrilamine Maleate
PYRILAMINE TANNATE
Triprolidine
Triprolidine Hydrochloride

Cochrane evidence based reviews: conjunctivitis, allergic

Genetic Tests for Allergic Conjunctivitis

Anatomical Context for Allergic Conjunctivitis

MalaCards organs/tissues related to Allergic Conjunctivitis:

40
Eye, Skin, T Cells, Liver, Lung, Thymus, Heart

Publications for Allergic Conjunctivitis

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 1814)
# Title Authors PMID Year
1
Clinical evaluation of total IgE in tears of patients with allergic conjunctivitis disease using a novel application of the immunochromatography method. 54 61
19779297 2009
2
Is serum total IgE levels a good predictor of allergies in children? 54 61
19813686 2009
3
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis. 61 54
19788663 2009
4
Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. 54 61
19558341 2009
5
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 54 61
20361659 2009
6
Serum allergen specific immunoglobulin E levels in patients with allergic conjunctivitis. 54 61
18850541 2008
7
The early efficacy of topical levocabastine in patients with allergic conjunctivitis. 54 61
17075271 2006
8
Allergens in Japanese patients with allergic conjunctivitis in autumn. 61 54
15389269 2005
9
Eotaxin-1 (CCL11) up-regulation in tears during seasonal allergic conjunctivitis. 61 54
15221302 2004
10
Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring. 61 54
15209463 2004
11
Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis. 54 61
14620169 2003
12
Human ocular mast cells. 61 54
12582326 2002
13
Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. 54 61
12431041 2002
14
Respiratory syncytial virus may be a pathogen in allergic conjunctivitis. 54 61
11995809 2002
15
The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. 61 54
11274077 2001
16
Genetics of allergic disease: evidence for organ-specific susceptibility genes. 61 54
11306967 2001
17
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 54 61
10756233 2000
18
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 61 54
10682966 2000
19
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 61 54
10606937 2000
20
[Measurement of total IgE in tears : the adaptation of an immunoenzyme technique and the value of investigating locally produced IgE in the diagnosis of chronic conjunctivitis]. 54 61
10432371 1999
21
Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis. 54 61
10400487 1999
22
Tear IgE concentrations in allergic conjunctivitis. 61 54
9683958 1998
23
Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. 61 54
9420138 1997
24
Characterization of cytokine mRNA transcripts in conjunctival cells in patients with allergic conjunctivitis. 54 61
9191598 1997
25
Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. 61 54
8911697 1996
26
Eosinophil cationic protein in tears in allergic conjunctivitis. 61 54
8759270 1996
27
A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. 61 54
8626992 1996
28
Measurement of interleukin-4 and histamine in superficial cells of conjunctiva in patients with allergic conjunctivitis. 61 54
8670730 1996
29
Interleukin-4 and IgE in seasonal allergic conjunctivitis. 61 54
8887388 1996
30
Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. 54 61
8789546 1996
31
Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. 54 61
7586697 1995
32
[Importance of the lacrymal levels (total IgE, specific IgE and albumin) for the study of allergic conjunctivitis]. 54 61
8185822 1994
33
The origin of keratopathy in chronic allergic eye disease: a histopathological study. 54 61
8253220 1993
34
Ocular manifestations in renal allograft recipients: An Indian perspective. 61
33727456 2021
35
Long-term remission of unusual plasmoacanthoma on the nasal canthus achieved by intralesional corticosteroid injection: Insights into the pathogenesis and treatment planning based on a literature review. 61
33739545 2021
36
The spectrum of allergic ocular diseases. 61
33276116 2021
37
Bilateral methicillin-resistant Staphylococcus aureus keratitis after corneal crosslinking for keratoconus in a child. 61
33689909 2021
38
Corneal Hydrops Associated with Keratoconus in a Young Girl with Severe Allergic Conjunctivitis. 61
33229290 2021
39
Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. 61
33773984 2021
40
Multiple Allergen Simultaneous Test-Immunoblot Assay for Immunoglobulin E Detection in Patients with Isolated Allergic Conjunctivitis. 61
33804507 2021
41
The safety of orthokeratology in myopic children and analysis of related factors. 61
32912740 2021
42
The influence of overnight orthokeratology on ocular surface and dry eye-related cytokines IL-17A, IL-6, and PGE2 in children. 61
32359968 2021
43
Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. 61
33463568 2021
44
Characterization of conjunctival microbiome dysbiosis associated with allergic conjunctivitis. 61
33080059 2021
45
Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. 61
33586015 2021
46
Current Knowledge in Allergic Conjunctivitis. 61
33631915 2021
47
Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. 61
33586090 2021
48
Association of Maternal History of Allergic Features with Preterm Pregnancy Outcomes in the Japan Environment and Children's Study. 61
33601376 2021
49
Adhesion of Pollen Particles to Daily Disposable Soft Contact Lenses. 61
33790684 2021
50
Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling. 61
33403505 2021

Variations for Allergic Conjunctivitis

Expression for Allergic Conjunctivitis

Search GEO for disease gene expression data for Allergic Conjunctivitis.

Pathways for Allergic Conjunctivitis

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 TLR3 SOCS5 SOCS3 RNASE3
2
Show member pathways
13.79 TNF TLR4 SOCS5 SOCS3 IL5 IL4
3
Show member pathways
13.65 TNF SOCS5 SOCS3 IL5 IL4 IL2
4
Show member pathways
13.52 TNF TLR4 TLR3 IL5 IL4 IL2
5
Show member pathways
13.38 TNF IL5 IL4 IL2 IL13 IL10
6
Show member pathways
13.32 TNF TLR4 TLR3 SOCS3 IL2 IL10
7
Show member pathways
13.32 TNF SOCS5 SOCS3 IL5 IL4 IL33
8
Show member pathways
12.97 TNF TLR4 TLR3 SOCS3 IL33 IL2
9 12.92 IL5 IL4 IL2 IL13 IFNG CXCL8
10
Show member pathways
12.88 TNF TLR4 TLR3 IL4 IL2 IFNG
11
Show member pathways
12.84 TNF RNASE3 IL5 IL4 IL2 IL13
12
Show member pathways
12.83 TNF SOCS5 SOCS3 IL4 IL2
13
Show member pathways
12.74 TNF IL4 IL2 IL10 IGHE IFNG
14
Show member pathways
12.74 TNF TLR4 IL5 IL4 IL2 IL10
15 12.73 TNF TLR3 SOCS3 IL4 IL2 IL10
16
Show member pathways
12.72 TNF SOCS3 IL10 IFNG ICAM1
17
Show member pathways
12.66 TNF SOCS3 IL2 IL10 IFNG
18
Show member pathways
12.66 TNF IL5 IL4 IL13 IGHE
19
Show member pathways
12.64 TNF TLR4 SOCS3 IL5 IL4 IL2
20
Show member pathways
12.6 TNF IL4 IL2 IFNG ICAM1
21
Show member pathways
12.6 SOCS5 SOCS3 IL5 IL4 IL2 IL13
22
Show member pathways
12.54 SOCS5 SOCS3 IL4 IGHE HRH1 CCL11
23
Show member pathways
12.51 TNF IL5 IL4 IL13 IFNG CXCL8
24
Show member pathways
12.46 TNF TLR4 TLR3 CXCL8
25
Show member pathways
12.44 TNF IL4 IL2 IFNG ICAM1
26
Show member pathways
12.44 TNF IL2 IL10 CXCL8 CCL11
27
Show member pathways
12.41 TNF TLR4 TLR3 IFNG CXCL8
28
Show member pathways
12.4 TNF SOCS3 IL5 IL4 IL2 IL13
29
Show member pathways
12.37 TNF TLR4 IL4 IL10 IFNG
30
Show member pathways
12.34 TNF TLR4 IL4 IFNG CXCL8 CCL11
31
Show member pathways
12.33 TNF TLR4 TLR3 CXCL8
32
Show member pathways
12.32 TNF TLR4 TLR3 IL33 IFNG
33 12.3 TNF TLR4 IL10 IFNG
34 12.26 TNF TLR4 TLR3 IFNG
35 12.24 TNF IL13 IL10 CXCL8
36 12.22 TNF TLR4 IL2 IL10 CXCL8
37 12.2 TNF TLR4 IL4 IL2 IFNG ICAM1
38
Show member pathways
12.18 TLR4 TLR3 IL5 IL2 IL13
39 12.18 TNF PTGDR2 IL5 IL4 IL2 IL10
40 12.07 TNF TLR4 IL10 IFNG CXCL8
41 12.03 TNF TLR4 ICAM1 CXCL8
42 12.02 TNF TLR4 IFNG ICAM1 CXCL8
43
Show member pathways
11.98 TLR4 ICAM1 FOXP3 CXCL8
44 11.98 IL5 IL4 IL2 IL13 IFNG ICAM1
45
Show member pathways
11.97 TLR4 TLR3 IL4 IFNG
46
Show member pathways
11.96 TNF TLR4 TLR3 IL2 IL10 IFNG
47
Show member pathways
11.94 TNF IL5 IL4 IL2 IFNG FOXP3
48 11.88 TNF TLR4 IL10 CXCL8
49 11.87 TNF IL2 IL10 IFNG
50 11.87 TNF IL5 IL4 IL13 CXCL8 CCL11

GO Terms for Allergic Conjunctivitis

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF RNASE3 IL5 IL4 IL33 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 IL13 IGHE ICAM1
3 extracellular space GO:0005615 9.44 TNF TLR3 RNASE3 IL5 IL4 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 TLR4 TLR3 PTGDR2 IL5 IL4 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF TLR4 TLR3 IL4 IL33 IL2
3 inflammatory response GO:0006954 10.11 TNF TLR4 TLR3 IL5 IL13 HRH1
4 positive regulation of gene expression GO:0010628 10.09 TNF TLR4 TLR3 IL4 IL33 IL13
5 defense response to bacterium GO:0042742 10.06 TNF TLR4 TLR3 RNASE3 IL10 IGHE
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.03 TNF TLR4 ICAM1 CCL11
7 response to lipopolysaccharide GO:0032496 10.03 TLR4 IL13 IL10 ICAM1 FOXP3
8 cellular response to lipopolysaccharide GO:0071222 10.02 TNF TLR4 IL10 ICAM1 CXCL8
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF TLR4 TLR3 ICAM1
10 chemotaxis GO:0006935 10 RNASE3 PTGDR2 CXCL8 CCL11
11 response to virus GO:0009615 9.97 TNF TLR3 IFNG FOXP3 CCL11
12 cellular response to interferon-gamma GO:0071346 9.96 TLR4 TLR3 ICAM1 CCL11
13 positive regulation of interleukin-6 production GO:0032755 9.96 TNF TLR4 TLR3 IL33 IFNG
14 positive regulation of tumor necrosis factor production GO:0032760 9.95 TLR4 TLR3 IL33 IFNG
15 negative regulation of tumor necrosis factor production GO:0032720 9.95 TLR4 IL4 IL10 FOXP3
16 negative regulation of interleukin-6 production GO:0032715 9.95 TNF TLR4 SOCS5 IL10 FOXP3
17 positive regulation of JNK cascade GO:0046330 9.93 TNF TLR4 TLR3
18 cellular response to interleukin-1 GO:0071347 9.93 ICAM1 CXCL8 CCL11
19 positive regulation of interferon-gamma production GO:0032729 9.93 TNF TLR4 TLR3 IL2
20 positive regulation of inflammatory response GO:0050729 9.93 TNF TLR4 TLR3 IL33 IL2 IFNG
21 cellular response to mechanical stimulus GO:0071260 9.92 TLR4 TLR3 IL13
22 regulation of growth GO:0040008 9.92 SOCS5 SOCS3 IFNG
23 apoptotic signaling pathway GO:0097190 9.92 TNF TLR4 TLR3
24 positive regulation of cytokine production GO:0001819 9.92 TNF TLR3 IL33 IL10 IFNG
25 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR4 TLR3
26 extrinsic apoptotic signaling pathway GO:0097191 9.91 TNF TLR3 IL33 IFNG
27 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.9 TNF TLR4 TLR3
28 positive regulation of interleukin-8 production GO:0032757 9.9 TNF TLR4 TLR3
29 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF TLR4 IFNG
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.9 TNF TLR4 IFNG ICAM1
31 negative regulation of interferon-gamma production GO:0032689 9.89 TLR4 IL33 IL10 FOXP3
32 positive regulation of B cell proliferation GO:0030890 9.89 TLR4 IL5 IL4 IL2 IL13
33 positive regulation of interleukin-12 production GO:0032735 9.88 TLR4 TLR3 IFNG
34 positive regulation of chemokine production GO:0032722 9.88 TNF TLR4 TLR3 IL33 IFNG
35 positive regulation of interleukin-10 production GO:0032733 9.87 TLR4 IL4 IL13
36 negative regulation of endothelial cell apoptotic process GO:2000352 9.87 IL4 IL13 IL10 ICAM1
37 negative regulation of inflammatory response GO:0050728 9.87 SOCS5 SOCS3 IL4 IL2 IL13 IL10
38 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL5 IL10
39 JAK-STAT cascade GO:0007259 9.85 SOCS5 SOCS3 IFNG
40 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF SOCS3 IL4 IL2 IL13 IFNG
41 negative regulation of osteoclast differentiation GO:0045671 9.84 TLR4 TLR3 IL4
42 positive regulation of macrophage activation GO:0043032 9.84 TLR4 IL33 IL13 IL10
43 negative regulation of interleukin-17 production GO:0032700 9.83 TLR4 IFNG FOXP3
44 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 TLR4 IL33 IFNG
45 regulation of regulatory T cell differentiation GO:0045589 9.81 IL2 IFNG FOXP3
46 microglial cell activation GO:0001774 9.8 TNF TLR3 IL4 IL13 IFNG
47 macrophage activation GO:0042116 9.79 TLR4 IL4 IL13
48 negative regulation of T-helper 17 cell differentiation GO:2000320 9.79 IL4 IL2 FOXP3
49 positive regulation of neuroinflammatory response GO:0150078 9.76 TNF IL33
50 I-kappaB phosphorylation GO:0007252 9.76 TLR4 TLR3

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL5 IL4 IL33 IL2 IL13
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL2 IL10

Sources for Allergic Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....